Researchers have demonstrated that inebilizumab reduced the risk of symptoms by 87 percent in patients with the rare affliction known as immunoglobulin G4-related disease (IgG4-RD).

WASHINGTON -- Patients with IgG4-related disease appeared to benefit from inebilizumab (Uplizna), currently approved for ...

IND clearance paves the way for Acepodia to enter the clinic for the first time with its autoimmune program ACE1831 is an allogeneic gamma delta T cell therapy ...